clonal fetal MSCs: cfMSCs to treat Chronic Obstructive Pulmonary Disease
Study summary
The primary objectives are to evaluate the safety and efficacy of infusion of fully characterized clonally derived fetal mesenchymal stem cells (cfMSCs) for the control of severe symptoms associated with moderate to severe chronic obstructive pulmonary disease.
Eligibility
Sex
ALL
Min age
40 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria:
1. Ability to understand the study protocol and the willingness to provide written informed consent;
2. Age 40-80 years old, male or female;
3. Diagnosed with moderate to severe COPD according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines (GOLD Ⅱ-Ⅳ).
4. Regular use of COPD conventional drugs for more than 3 months, and the condition is stable for more than 4 weeks;
5. ineffective clinical treatment;
6. Life expectancy \> 6 months;
7. At least six months smoking cessation, including non-smoking during the treatment and follow-up periods of the study.
Exclusion Criteria:
1. Combined with other serious lung diseases: asthma, active pulmonary tuberculosis, bronchiectasis, pulmonary embolism, interstitial lung disease, pulmonary hypertension, etc.;
2. A history of lung surgery (pneumonectomy, lung volume reduction surgery, etc.) or bronchial intervention surgery within 12 months;
3. Invasive or non-invasive mechanical ventilation history within 4 weeks, or moderate to severe acute exacerbation of COPD within 4 weeks;
4. Negative for HIV, HCV or syphilis serology;
5. A history of malignant tumors or malignant tumors under treatment;
6. Autoimmune diseases requiring long-term use of glucocorticoids or immunosuppressants;
7. Poorly controlled diabetes (fasting blood glucose \> 10.0 mmol/L) or severe metabolic diseases;
8. A history of alcohol or drug abuse, or mental diseases that cannot cooperate with the study;
9. Pregnancy or breastfeeding.
10. Unable or unwilling to comply with study specific schedules or procedures.
Primary outcome measure(s)
Number of patients with adverse events. — 24 weeks Determine the safety and tolerability of clonal fetal Mesenchymal Stem Cell (cfMSC) therapy with Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, including acute reactions, fever and other adverse events.
Trial sites (1)
Facility
City
Region
Status
Shenzhen Geno-immune Medical Institute
Shenzhen
Guangdong
More Shenzhen Geno-Immune Medical Institute trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.